By Sally Vazquez-Castellanos, Esq.
Published on November 4, 2026 at approximately 8:57 am.
OPINION: Marketing plays an important role in that process. A campaign establishes expectations among investors, commercial partners, patients, and employees. Once those expectations become financing commitments, partnership agreements, and launch schedules, they can place substantial downward pressure on the organization. Scientists and engineers may be expected to meet deadlines established around a commercial narrative before technical uncertainties have been resolved. Legal, privacy, and security personnel may face similar pressure to support expansion.
I believe this dynamic deserves attention in understanding Theranos. Former agency personnel have described questioning proposed claims and requesting substantiation. Their accounts suggest the importance of examining how concerns moved through the organization and whether those responsible for evaluating the technology had sufficient authority to change what was being promised. This does not mean every marketing participant understood the company’s technical problems or shared responsibility for its misconduct. (abcnews.com)
For me, the technology also raises questions beyond diagnostic accuracy. A health product that incorporates wireless communications, remote processing, or cloud infrastructure requires protection throughout the collection, transmission, storage, and use of sensitive information. These systems can create security vulnerabilities and dependencies that patients cannot readily assess. A successful laboratory measurement would not, by itself, establish that the surrounding information systems were secure.
I would want to understand who controlled the information, which service providers could access it, where processing occurred, and whether access or transfers crossed national borders. Those questions require examination of the actual architecture, contracts, security controls, and practices. I am not asserting that a particular breach or unlawful transfer occurred at Theranos. My point is that these responsibilities form part of the technological undertaking and should influence how confidently—and how quickly—it is marketed.
The Commerce Department and national-security dimensions require similarly careful research. International commerce, applicable data-transfer frameworks, export controls, and foreign access to sensitive information can involve different legal requirements. Their relevance must be established for the particular product, transaction, and period. These considerations belong in an assessment of a company’s technological promise, without assuming an undisclosed government role or treating national security as an explanation for demonstrated technical failures.
I offer Facebook and Meta, and the concerns surrounding TikTok and its predecessor Musical.ly, as parallel stories that provide context for my thinking. I am not attempting to resolve those controversies here or equate their legal circumstances with Holmes’s case. They illustrate why I approach assurances about connected technologies cautiously, particularly when children, parents, personal information, and cross-border access are involved.
COVID-19 provides a later perspective on the importance of these responsibilities. Theranos announced its dissolution in 2018, before the pandemic. Nevertheless, the subsequent public-health crisis underscored the importance of dependable diagnostics, clear communication, and trustworthy health-information systems. That experience informs how I now view the seriousness of the promise Theranos was making. (finance.yahoo.com)
The separate Wen Ho Lee privacy matter also informs my concern about public narratives. His later litigation over disclosures associated with a national-security investigation brought individual privacy and journalists’ protection of confidential sources into conflict. I cite it as a reminder to examine carefully how sensitive information is handled and how a person becomes publicly defined by a controversy. A name, ancestry, or professional association should never substitute for evidence. (rcfp.org)
For these reasons, I find a documentary treatment that makes light of the Holmes matter’s broader implications troubling. The story involves patients, employees, investors, commercial partners, and substantial questions about technological judgment. Those considerations deserve attention alongside the personalities involved.
My view is that the Holmes case should prompt closer examination of how a company’s public promise affects its internal decisions. Marketing pressure does not excuse deception. Nor does a conviction eliminate the value of examining the organizational pressures and technological complexities surrounding the conduct. Responsible development requires room to narrow a claim, postpone a launch, address a security concern, or acknowledge that a product is not ready. In health technology, those decisions are part of earning public trust.
Legal disclaimer: This commentary expresses my personal opinions and is provided for general informational purposes only. It is not legal advice and does not create an attorney-client relationship. References to separate cases and controversies provide context and do not imply an established connection or wrongdoing beyond the cited record.
ChatGPT disclosure: I used ChatGPT to assist in developing, organizing, and refining this opinion. The views expressed are my own.